MedTrace Logo

Elonva in Combination With Hp-FSH Versus Elonva With Low Dose hCG

NCT03208972 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2021-02-03

No results posted yet for this study

Summary

The study compares in a randomized controlled way two stimulation methods. One of these stimulation methods implements a new insight in ovarian follicular growth. If this novel method of stimulation proves to be as efficient as the classical stimulation protocols, there might be a dramatic reduction of the costs of the medical therapy in IVF, thus reducing also the overall IVf costs significantly.

Conditions

Interventions

DRUG

low dose hCG

DRUG

hp-FSH

DRUG

Corifollitropin Alfa

Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group. \<60 kg: Elonva 100 MCG \> 60 kg: Elonva 150 MCG

Sponsors & Collaborators

  • Onze Lieve Vrouw Hospital

    collaborator OTHER

  • AZ Jan Palfijn Gent

    lead OTHER

Principal Investigators

  • Wim Decleer, MD · FERTILITY CENTER AZ JAN PALFIJN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03208972 on ClinicalTrials.gov